Neurogene Revenue and Competitors
Estimated Revenue & Valuation
- Neurogene's estimated annual revenue is currently $18M per year.
- Neurogene's estimated revenue per employee is $155,000
- Neurogene's total funding is $184M.
Employee Data
- Neurogene has 116 Employees.
- Neurogene grew their employee count by 17% last year.
Neurogene's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder & CEO | Reveal Email/Phone |
2 | VP Clinical and Translational Biomarker Strategy | Reveal Email/Phone |
3 | VP Regulatory Affairs | Reveal Email/Phone |
4 | Head Manufacturing | Reveal Email/Phone |
5 | SVP, Early Clinical and Translational Research | Reveal Email/Phone |
6 | SVP, Business Operations | Reveal Email/Phone |
7 | Head Quality Assurance | Reveal Email/Phone |
8 | SVP, Technical Operations | Reveal Email/Phone |
9 | SVP, Clinical Development | Reveal Email/Phone |
10 | SVP, Regulatory Affairs, Quality Assurance, and Quality Control | Reveal Email/Phone |
Neurogene Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Neurogene?
Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders. At Neurogene, we are working to provide medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their families. For children, our goal is simple: to enable them to have a healthier future. For their families, we want to make their lives better: when one family member is neurologically impaired, there is a heavy burden on caregivers ᅢᄁ¬ツᆲ¬タワ whether it is caring for an infant who will not live to see her third birthday, communicating with a son who doesnᅢᄁ¬ツᆲ¬トᄁt speak, or attempting to control a teenager in the throes of a self-injurious tantrum. We are building a team of passionate, driven individuals who envision a world in which all families have access to genetic medicines, even if the disorder is exceedingly rare. To learn more, please visit http://www.neurogene.com/careers/.
keywords:N/A$184M
Total Funding
116
Number of Employees
$18M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Neurogene News
"Ivan has a rare neurogenetic spectrum disorder which requires that he has consistent care," Ursillo said. "The disorder that ivan has,...
The recent start of Neurogene Inc.'s first-in-human trial testing NG-101 in ceroid lipofuscinosis type 5 (CLN5) Batten disease (BD) drew...
NEW YORK--(BUSINESS WIRE)--Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the completion of a $115 million Series B financing. The financing round was led by EcoR1 Capital, with participa ...
Neurogene, Inc., a NYC-based company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, raised $68.5m in Series A financing. Investors included Samsara BioCapital, EcorR1 Capital, Cormorant Asset Management, Redmile Group and ...
NEW YORK--(BUSINESS WIRE)--Neurogene, Inc., a company founded with a mission to bring life-changing medicines to patients and families affected by rare neurological diseases, today announced a $68.5 million Series A financing. Investors included Samsara BioCapital, EcorR1 Capital, Cormorant Asse ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $20.2M | 116 | 7% | N/A |
#2 | $16.2M | 116 | -19% | N/A |
#3 | $31.3M | 116 | -1% | N/A |
#4 | $23.8M | 116 | -13% | N/A |
#5 | $20.9M | 116 | 5% | N/A |